Cargando…

MON-320 Inter-Rater Reliability of T2 MRI Intensity of Somatotroph Adenomas; Endocrinologists vs. Neuroradiologist Pilot Study

Background MRI T2 hypointensity of growth hormone (GH) secreting pituitary adenomas (PA) has been associated with better biochemical response to somatostatin receptor ligands and has been suggested to be useful in selecting patients with expected favorable response for pre- and post-surgery medical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Varlamov, Elena V, Hinojosa-Amaya, José Miguel, Ting, Dawn Lim Shao, Fleseriu, Maria, Prola, Joao
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7209263/ http://dx.doi.org/10.1210/jendso/bvaa046.970

Ejemplares similares

MON-277 Patient Health Questionnaire 9 (PHQ-9) and Barrat Impulsivity Scale (BIS-11); Tools to Identify Side Effects of Dopamine Agonist Treatment in Patients with Pituitary Adenomas
por: Hinojosa-Amaya, José Miguel, et al.
Publicado: (2020)

Pituitary Somatotroph Adenoma Cell-Derived Exosomes: Characterization of Novel Non-Hormonal Functions
por: Zhou, Cuiqi, et al.
Publicado: (2021)

ODP311 Giant-versus Macroadenomas: Does Size Really Matter in Pituitary Somatotroph Adenomas?
por: Sendur, Suleyman Nahit, et al.
Publicado: (2022)

MON-308 Pituitary Magnetic Resonance Imaging in the Postoperative Follow-Up of Patients with Acromegaly, Less Is More!
por: Fernandes, Stuti, et al.
Publicado: (2020)

Somatotroph Adenomas have a Predilection to Invade the Cavernous Sinus and Resection of the Medial Wall of the Cavernous Sinus Offers the Highest Potential for Biochemical Remission in Acromegaly
por: Mohyeldin, Ahmed, et al.
Publicado: (2021)

MON-LB081 Pituitary Adenomas: A Pan-genomic Classification
por: NEOU, Mario, et al.
Publicado: (2019)

MON-426 Non Functioning Pituitary Adenoma And Schizophrenia: An Incidental Association?
por: Shaamile, Ferrah, et al.
Publicado: (2019)

MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas
por: Soto, Alfonso, et al.
Publicado: (2019)

MON-299 Risk Factors of Re-Growth of Non-Functional Pituitary Adenomas
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

MON-255 Oral Contraceptive Pills Mask an Aggressive Crooke’s Cell Pituitary Adenoma
por: Gnanapragasam, Helen Prathiba, et al.
Publicado: (2020)

MON-269 FGFR-4 Expression in Pituitary Adenomas Is Associated with Aggressive Tumor Features
por: Kadioglu, Pinar, et al.
Publicado: (2020)

MON-462 Cytokine Network in Pituitary Adenomas and Its Role in the Tumor Microenvironment: Focus on Macrophages
por: Marques, Pedro, et al.
Publicado: (2019)

MON-LB082 Elevated Expression of KISSR Is Associated with Secretory Function of Functioning Gonadotroph Adenomas
por: Wang, Linjie, et al.
Publicado: (2019)

MON-263 Renal Cell Cancer Metastasis to the Pituitary Masquerading as a Non-Functioning Adenoma
por: Vedere, Tarunya, et al.
Publicado: (2020)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

MON-309 Prevalence of Silent Corticotroph Adenomas in a Large Cohort of Nonfunctioning Pituitary Adenomas: Plasma Proopiomelanocortin(POMC) Levels and Response to Pasireotide LAR
por: Reyes-Vidal, Carlos, et al.
Publicado: (2020)

MON-303 Giant Growth Hormone Secreting Pituitary Adenomas: A Single Institution Case Series
por: Koylu, Bahadir, et al.
Publicado: (2020)

MON-440 Cyberknife Radiosurgery for Functional and Non-Functional Pituitary Adenomas: Long-Term Single-Center Experience
por: Yuen, Kevin, et al.
Publicado: (2019)

MON-326 Non Functioning Pituitary Adenomas (NFPA): Sex Related Differences in Presentation, Clinical Features and Outcomes
por: Rosmino, Josefina, et al.
Publicado: (2020)

MON-295 Desmopressin Test in Silent Corticothoph Pituitary Adenomas, a Preliminary Study - a Comparison with Cushing Disease
por: Huayllas, Martha Katherine, et al.
Publicado: (2020)

MON-237 Primary Pituitary Lymphoma - an Unusual Guest in the Sella!
por: Harjanto, Sumitro, et al.
Publicado: (2020)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

MON-304 Prolactin as a Surrogate Marker to Predict Long Term Postoperative Hypopituitarism After Transsphenoidal Resection of Pituitary Adenomas
por: German, Massiell, et al.
Publicado: (2020)

Functioning Pituitary Adenomas – Current Treatment Options and Emerging Medical Therapies
por: Varlamov, Elena V, et al.
Publicado: (2019)

FRI320 The Various Clinical Outcomes Of Giant Prolactinomas In Men
por: Gilis-Januszewska, Aleksandra, et al.
Publicado: (2023)

MON-332 Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing’s Syndrome (LOGICS): A Double-Blind, Placebo-Controlled, Withdrawal Study
por: Zacharieva, Sabina Z, et al.
Publicado: (2020)

MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect?
por: Marques, Pedro, et al.
Publicado: (2019)

MON-430 To B, or Not to B
por: Pradeep, Pallavi, et al.
Publicado: (2019)

MON-LB46 Thyrotropinoma and Pregnancy
por: Namboodiri, Divya, et al.
Publicado: (2020)

ODP320 Immune Organs Enlarged in Acromegaly: Evaluation of Thymus Volume in Patients with Acromegaly
por: Nahit Sendur, Suleyman, et al.
Publicado: (2022)

MON-LB57 Impact of Imputation Method and Response Cutoffs on Results From the Phase 3 OPTIMAL Study of Oral Octreotide Capsules in Adult Patients With Acromegaly
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-305 Clinical Features in Patients with Hypercorticism
por: Negmatova, Gulzoda Shuhratovna, et al.
Publicado: (2020)

MON-439 Evaluation of Surgical Resection Goal and Its Relationship to the Extent of Resection and Patient Outcomes in 221 Patients following Transsphenoidal Surgery for Nonfunctioning Pituitary Adenomas: Data from the TRANSSPHER Study
por: Little, Andrew, et al.
Publicado: (2019)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-314 Analysis of Adverse Events in Adult Patients with Acromegaly Receiving Oral Octreotide Capsules: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Labadzhyan, Artak, et al.
Publicado: (2020)

MON-425 SIADH with Epistaxis: Rule out Esthesioneuroblastoma
por: Diamond, Samantha, et al.
Publicado: (2019)

MON-266 The Association Between Prolactinomas and Weight Gain
por: Tariq, Zunera, et al.
Publicado: (2020)

MON-289 Pituitary Metastasis: A Systematic Review
por: Parekh, Shrina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_uape2d8krdd193psa7eqhvul4u